NCPE Recommendations

We have completed a Rapid Review for this medicine. We believe that a more detailed assessment (a full health technology assessment) is needed. This will allow us to recommend to the HSE whether or not to provide this medicine. A more detailed assessment is needed because it is not clear that the medicine works as well or better than other ways to manage this condition, or it is not clear that the medicine is value for money.
The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a Rapid Review for this medicine. We believe that a more detailed assessment (a full health technology assessment) is needed. This will allow us to recommend to the HSE whether or not to provide this medicine. We believe that the medicine may work as well or better than other ways to manage this condition.

The price of the medicine is higher than other treatments used for this condition, and it is not clear that the medicine is value for money. A full health technology assessment may not be needed if the HSE can agree a suitable price reduction with the pharmaceutical company.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

We have completed a Rapid Review for this medicine. We recommend that the HSE consider providing this medicine. We believe the medicine may work as well or better than other ways to manage this condition, and we believe the medicine is value for money. We believe enough information was provided in the Rapid Review. Therefore, a more detailed assessment (a full health technology assessment) is not needed.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a Rapid Review for this medicine. We recommend that the HSE consider not providing this medicine unless the HSE can agree a suitable price reduction with the pharmaceutical company. The price of the medicine is higher than other ways to manage this condition, and we believe that the medicine is not value for money. We believe enough information was provided in the Rapid Review. Therefore, a more detailed assessment (a full health technology assessment) is not needed.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a Rapid Review for this medicine. We believe that a more detailed assessment (a full health technology assessment) should not be done at this time because there is not enough information on how well the medicine works. We recommend that the HSE consider not providing this medicine. We will assess this medicine again when we get more information from the pharmaceutical company.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a full health technology assessment of this medicine. We recommend that the HSE consider providing this medicine. We believe the medicine may work as well or better than other ways to manage this condition, and we believe the medicine is value for money.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a full health technology assessment for this medicine. We recommend that the HSE consider providing this medicine if the HSE can agree a suitable price reduction with the pharmaceutical company. We believe the medicine may work as well or better than other ways to manage this condition. However, the price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is not value for money.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a full health technology assessment for this medicine. We recommend that the HSE consider not providing this medicine unless the HSE can agree a suitable price reduction with the pharmaceutical company. This is because we believe the medicine may work as well or better than other ways to manage this condition. However, the price of the medicine too high compared with other ways to manage this condition, and we believe that the medicine is very poor value for money.

or

we believe it is not clear that the medicine works as well or better than other ways to manage this condition. The price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is very poor value for money.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have completed a full health technology assessment for this medicine. We recommend that the HSE consider not providing this medicine. There are differing reasons why we recommend not reimbursing a medicine. The reason for not recommending the medicine will be explained in the summary documents for the medicine.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.